scholarly journals Use of a novel oleaginous microorganism as a potential source of lipids for weanling pigs1,2

2017 ◽  
Vol 1 (2) ◽  
pp. 201-207
Author(s):  
J. A. Carroll ◽  
T. B. Schmidt ◽  
T. R. Callaway ◽  
J. G. Wilson ◽  
J. R. Donaldson
Keyword(s):  
Serum Lipids ◽  
Metabolic Response ◽  
Enterobacter Cloacae ◽  
Variant Form ◽  
The Novel ◽  
Weanling Pigs ◽  
Available Energy ◽  
Oleaginous Microorganism ◽  
Daily Dose ◽  
Immature Immune System

Abstract Weanling pigs are at risk of succumbing to illness due to an immature immune system and insufficient supply of available energy at the time of weaning. This study was aimed at determining whether oleaginous bacteria could serve as a source of lipids to weanling pigs. Weanling pigs were provided a daily dose of 1×109 colony fomring unit (CFU) = kg−1 of the novel oleaginous Enterobacter cloacae strain JD6301 or JD8715 (which is a variant form of JD6301 capable of producing extracellular triglycerides) via oral gavage for 5 d. Serum was collected every 6 h and intestinal samples were collected at 6 d. Providing pigs with JD6301 or JD8715 significantly increased serum concentrations of triglycerides and non-esterified fatty acids (NEFA) within 72 h. Additionally, the JD6301 and JD8715 strains were able to survive within the gastrointestinal tract throughout the duration of the study. These results suggest that providing Enterobacter cloacae can increase the serum lipids in the pigs, thus potentially providing an additional source of energy to animals during times of stress. This could potentially help improve the metabolic response of animals during times of stress.

scholarly journals Draft Genome Sequence of the Novel Enterobacter cloacae Strain amazonensis, a Highly Heavy Metal-Resistant Bacterium from a Contaminated Stream in Amazonas, Brazil

2018 ◽  
Vol 6 (22) ◽  
Author(s):  
Maria Clara Tavares Astolfi ◽  
Elen Bethleen de Souza Carvalho ◽  
Adriane Menezes de Barros ◽  
Marcelo Valente Pinto ◽  
Luna Barrôco de Lacerda ◽  
...  
Keyword(s):  
Heavy Metals ◽  
Heavy Metal ◽  
Draft Genome ◽  
Enterobacter Cloacae ◽  
The Novel ◽  
Biotechnological Applications ◽  
Toxic Compounds ◽  
Content Type ◽  
Genes Encoding ◽  
Heavy Metal Resistant

ABSTRACT Here, we report the draft genome of the Enterobacter cloacae strain amazonensis, a bacterium highly resistant to mercury that was isolated from a metal- and sewage-contaminated stream in Amazonas, Brazil. The exploration of the 5.0-Mb genome revealed 104 genes encoding resistance to toxic compounds and heavy metals, highlighting the potential biotechnological applications of this strain.

scholarly journals Novel Carbapenemases FLC-1 and IMI-2 Encoded by an Enterobacter cloacae Complex Isolated from Food Products

2019 ◽  
Vol 63 (6) ◽  
Author(s):  
Michael S. M. Brouwer ◽  
Kamaleddin H. M. E. Tehrani ◽  
Michel Rapallini ◽  
Yvon Geurts ◽  
Arie Kant ◽  
...  
Keyword(s):  
General Population ◽  
Enterobacter Cloacae ◽  
Hydrolytic Activity ◽  
Resistant Bacteria ◽  
Human Consumption ◽  
The Novel ◽  
Antibiotic Resistant ◽  
Content Type ◽  
Class A ◽  
Enterobacter Cloacae Complex

ABSTRACT Food for human consumption is screened widely for the presence of antibiotic-resistant bacteria to assess the potential for transfer of resistant bacteria to the general population. Here, we describe an Enterobacter cloacae complex isolated from imported seafood that encodes two carbapenemases on two distinct plasmids. Both enzymes belong to Ambler class A β-lactamases, the previously described IMI-2 and a novel family designated FLC-1. The hydrolytic activity of the novel enzyme against aminopenicillins, cephalosporins, and carbapenems was determined.

scholarly journals Outbreak of Infection Caused by Enterobacter cloacae Producing the Novel VEB-3 Beta-Lactamase in China

2005 ◽  
Vol 43 (2) ◽  
pp. 826-831 ◽  
Author(s):  
X. Jiang ◽  
Y. Ni ◽  
Y. Jiang ◽  
F. Yuan ◽  
L. Han ◽  
...  
Keyword(s):  
Enterobacter Cloacae ◽  
Beta Lactamase ◽  
The Novel

scholarly journals Coidentification of mcr-4.3 and blaNDM-1 in a Clinical Enterobacter cloacae Isolate from China

2018 ◽  
Vol 62 (10) ◽  
Author(s):  
Bhakti Chavda ◽  
Jingnan Lv ◽  
Mengyun Hou ◽  
Kalyan D. Chavda ◽  
Barry N. Kreiswirth ◽  
...  
Keyword(s):  
Lipid A ◽  
Susceptibility Testing ◽  
Enterobacter Cloacae ◽  
Mass Spectrometry Analysis ◽  
Ionization Mass ◽  
The Novel ◽  
Laser Desorption Ionization ◽  
Content Type ◽  
Spectrometry Analysis ◽  
High Level

ABSTRACT We describe the first report of a clinical colistin-resistant ST84 Enterobacter cloacae isolate coharboring mcr-4.3 (previously named mcr-4.2) and blaNDM-1 from a patient in China. The blaNDM-1-harboring IncX3 plasmid and the novel mcr-4.3-harboring ColE plasmid were completely sequenced. Although this isolate showed a high level of resistance to colistin, mcr-4.3 plasmid transformation, gene subcloning, susceptibility testing, and lipid A matrix-assisted laser desorption ionization mass spectrometry analysis indicated that mcr-4.3 itself does not confer resistance to colistin.

Phase II trial of sunitinib malate and lomustine in patients with temozolomide refractory recurrent low-grade and anaplastic gliomas.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 2050-2050
Author(s):  
Johnny Duerinck ◽  
Stephanie Du Four ◽  
An Van Binst ◽  
Hendrik Everaert ◽  
Alex Michotte ◽  
...  
Keyword(s):  
Metabolic Response ◽  
Clinical Investigation ◽  
Progression Free Survival ◽  
Recurrent Glioblastoma ◽  
Anaplastic Glioma ◽  
Low Grade ◽  
Meaningful Activity ◽  
Anaplastic Gliomas ◽  
Daily Dose ◽  
Heavily Pretreated

2050 Background: Recurrent low-grade and anaplastic gliomas eventually transform to a higher grade that is characterized by neo-angiogenesis. Sunitinib inhibits multiple tyrosine kinase receptors (including VEGFR, PDGFR and c-Kit) but has no meaningful activity as a mono-therapy for recurrent glioblastoma when given at a daily dose of 37,5 mg (Neyns et al. J Neurooncol. 2011). We investigated sunitinib in combination with lomustine (CCNU) for the treatment of patients (pts) with temozolomide (TMZ) refractory recurrent low-grade or anaplastic glioma. Methods: Pts received a daily dose of 25 mg sunitinib for 28 consecutive days followed by a 14 days treatment-free interval. CCNU was administered as a single dose (80 mg/m²) on day 14 of a 6w cycle. T1 ± Gd and T2/FLAIR weighted MRI images were obtained q6 wks. 18FET-PET was performed at baseline and reassessed in responding pts. Results: 13 pts were enrolled (mean age 40 [range 33-49]; M/F 8/5; KPS 80-90/70-60: 8/5 pts). All pts had PD following surgery, RT and TMZ. In 7 pts, treatment was initiated at 2nd recurrence, in 4 pts at 3rd recurrence and in 2 pts at the 4th recurrence. Most frequent AEs where fatigue (gr 2: n= 3; gr 3: n= 1), thrombopenia (gr 2: n= 1 gr 3: n= 3 gr4: n= 1), neutropenia (gr 2: n= 2; gr3: n= 2; gr4: n= 2) and lymphopenia (gr 2: n=1; gr 3: n=2; gr 4: n=1). In 5/13 pts CCNU had to be discontinued because of AEs. Treatment with sunitinib was continued in these cases without reoccurrence of AEs. BOR according to RANO criteria: 1 CR, 1 PR (not-confirmed) and 2 SD (DCR: 4/13= 31%). In the patient with CR, FET-PET indicated a complete metabolic response. After a mean FU of 7 mths (range 2 -19), 5 pts are alive. The 6-month PFS is 23% (3/13 pts); median PFS is 1,8 mths (95%CI 1.0 - 2,7). A durable disease control was obtained in 3 pts (TTP respectively 14.8, 11.8+ and 19.2+ mths). Conclusions: in this heavily pretreated population with recurrent low-grade and anaplastic glioma the combination of sunitinib and CCNU is associated with acceptable toxicity and offers a durable progression-free survival in a subgroup of pts. Molecular predictive factors identifying the sensitive population would be needed to justify further clinical investigation of this combination.

scholarly journals Genetic and Kinetic Characterization of the Novel AmpC β-Lactamases DHA-6 and DHA-7

2014 ◽  
Vol 58 (11) ◽  
pp. 6544-6549 ◽  
Author(s):  
Francisco José Pérez-Llarena ◽  
Laura Zamorano ◽  
Frédéric Kerff ◽  
Alejandro Beceiro ◽  
Patricia García ◽  
...  
Keyword(s):  
Enterobacter Cloacae ◽  
Slight Reduction ◽  
The Novel ◽  
Incompatibility Group ◽  
Content Type ◽  
E Coli ◽  
Natural Variants ◽  
Tertiary Protein Structure ◽  
Hydrolysis Of

ABSTRACTDuring a Spanish surveillance study, two natural variants of DHA β-lactamases, DHA-6 and DHA-7, were found, with the replacements Ala226Thr and Phe322Ser, respectively, with respect to DHA-1. The DHA-6 and DHA-7 enzymes were isolated fromEscherichia coliandEnterobacter cloacaeclinical isolates, respectively. The aim of this study was to genetically, microbiologically, and biochemically characterize the DHA-6 and DHA-7 β-lactamases. TheblaDHA-6andblaDHA-7genes were located in the I1 and HI2 incompatibility group plasmids of 87.3 and 310.4 kb, respectively. The genetic contexts ofblaDHA-6andblaDHA-7were similar to that already described for theblaDHA-1gene and included theqnrB4andaadAgenes. The MICs for cephalothin, aztreonam, cefotaxime, and ceftazidime were 8- to 32-fold lower for DHA-6 than for DHA-1 or DHA-7 expressed in the same isogenicE. coliTG1 strain. Interestingly, the MIC for cefoxitin was higher in the DHA-6-expressing transformant than in DHA-1 or DHA-7. Biochemical studies with pure β-lactamases revealed slightly lower catalytic efficiencies of DHA-6 against cephalothin, ceftazidime, and cefotaxime than those of DHA-1 and DHA-7. To understand this behavior, stability experiments were carried out and showed that the DHA-6 protein displayed significantly higher stability than the DHA-1 and DHA-7 enzymes. The proximity of Thr226 to the N terminus in the tertiary protein structure in DHA-6 may promote this stabilization and, consequently, may induce a slight reduction in the dynamic of this enzyme that primarily affects the hydrolysis of some of the bulkiest antibiotics.

scholarly journals Uncovering the novel Enterobacter cloacae complex species responsible for septic shock deaths in newborns: a cohort study

2021 ◽  
Author(s):  
Delphine Girlich ◽  
Souad Ouzani ◽  
Cécile Emeraud ◽  
Lauraine Gauthier ◽  
Rémy A Bonnin ◽  
...  
Keyword(s):  
Septic Shock ◽  
Cohort Study ◽  
Enterobacter Cloacae ◽  
The Novel ◽  
Complex Species ◽  
Enterobacter Cloacae Complex

scholarly journals Kinetic and physical studies of β-lactamase inhibition by a novel penem, BRL 42715

1994 ◽  
Vol 303 (3) ◽  
pp. 825-830 ◽  
Author(s):  
T H Farmer ◽  
J W J Page ◽  
D J Payne ◽  
D J C Knowles
Keyword(s):  
Mass Spectrometry ◽  
Staphylococcus Aureus ◽  
Klebsiella Pneumoniae ◽  
Electrospray Mass Spectrometry ◽  
Enterobacter Cloacae ◽  
Beta Lactamase ◽  
The Novel ◽  
Beta Lactamases ◽  
Enzyme Recovery ◽  
Mass Increase

The interactions of Staphylococcus aureus, Bacillus cereus I, TEM, Klebsiella pneumoniae K1 and Enterobacter cloacae P99 beta-lactamases with the novel penem inhibitor BRL 42715 were investigated kinetically and, in some cases, by electrospray mass spectrometry (e.s.m.s.). All the beta-lactamases were rapidly inactivated by BRL 42715, with second-order rate constants ranging from 0.17 to 6.4 microM-1.s-1. The initial stoichiometry of beta-lactamase inhibition was essentially 1:1, with the exception of the K1 enzyme. In this instance about 20 molecules of BRL 42715 were hydrolysed before the enzyme was completely inhibited. Inhibited beta-lactamases did not readily regain activity in the absence of BRL 42715, the half-lives for regeneration of free enzyme ranging from 5 min for the K1 beta-lactamase to over 2 days for the staphylococcal enzyme. Recovery of activity was incomplete for TEM-1, K1 and P99 beta-lactamases, suggesting partitioning of the inhibited enzymes to give a permanently (or at least very stable) inactivated species. Examination of the interactions of the penem with TEM, B. cereus I and P99 beta-lactamases by e.s.m.s. also showed rapid and stoichiometric binding of the inhibitor. In all cases a mass increase of 264 Da over the native enzyme was observed, corresponding to the molecular mass of BRL 42715, showing that no fragmentation of the penem occurred on reaction with the beta-lactamases.

Sign in / Sign up

Export Citation Format

Share Document